{
    "nct_id": "NCT02730247",
    "official_title": "A Phase II Clinical Trial of the Safety and Efficacy of the Addition of Ramucirumab to Nab-paclitaxel in Previously Treated Patients With Advanced Non-small Cell Lung Cancer (NSCLC)",
    "inclusion_criteria": "All patients must have or meet the following:\n\n* Histologically or cytologically confirmed Stage IV (AJCC 7) non-small cell lung cancer.\n* Measurable disease, defined as at least one lesion that can be accurately measured in at least one dimension as ≥20 mm with conventional techniques or as ≥10 mm with spiral CT scan, MRI, or calipers by clinical exam.\n* Received at least one prior platinum-based chemotherapy for locally advanced or metastatic disease. Prior bevacizumab as 1st line and/or maintenance therapy is allowed. Prior nivolumab is allowed.\n* Age ≥18 years.\n* ECOG performance status ≤2\n* Life expectancy of greater than 12 weeks.\n* Adequate liver function\n* Adequate hematologic function\n* Not have cirrhosis at a level of Child-Pugh B (or worse) or cirrhosis (any degree) with a history of hepatic encephalopathy or clinically meaningful ascites resulting from cirrhosis.\n* Adequate renal function\n* Urinary protein of ≤1+ on dipstick or routine urinalysis (UA).\n* Adequate coagulation function. Patients receiving warfarin must be switched to low molecular weight heparin and have achieved stable coagulation profile prior to first dose of protocol therapy.\n* Treated and clinically stable brain metastases are allowed.\n* Adequate contraceptive use.\n* < Grade 2 pre-existing peripheral neuropathy.\n* Ability to understand and the willingness to sign a written informed consent document.\nHealthy volunteers allowed\nMust have minimum age of 18 Years",
    "exclusion_criteria": "* Patients who have had chemotherapy or radiotherapy within 4 weeks (6 weeks for nitrosoureas or mitomycin C) prior to entering the study or those who have not recovered from adverse events due to agents administered more than 4 weeks earlier.\n* Patients with previous intolerance to ramucirumab.\n* Patients who are receiving any other investigational agents.\n* History of allergic reactions attributed to compounds of similar chemical or biologic composition to ramucirumab or nab-paclitaxel.\n* Patients with untreated CNS metastases.\n* Patients with significant bleeding disorders, vasculitis, or who experienced Grade 3/4 gastrointestinal (GI) bleeding within 3 months prior to enrollment.\n* History of deep vein thrombosis, pulmonary embolism, or any other significant thromboembolism during the 3 months prior to enrollment.\n* Any arterial thromboembolic events, within 6 months prior to enrollment.\n* History of uncontrolled hereditary or acquired thrombotic disorder.\n* Uncontrolled or poorly-controlled hypertension.\n* A serious or nonhealing wound, ulcer, or bone fracture within 28 days prior to enrollment.\n* Major surgery within 28 days prior to enrollment, or subcutaneous venous access device placement within 7 days prior to enrollment.\n* Chronic antiplatelet therapy, including aspirin, nonsteroidal anti-inflammatory drugs (NSAIDs, including ibuprofen, naproxen, and others), dipyridamole or clopidogrel, or similar agents. Once-daily aspirin use (maximum dose 325 mg/day) is permitted.\n* Elective or planned major surgery scheduled during the course of the clinical trial.\n* Hemoptysis (defined as bright red blood or ≥ 1/2 teaspoon) within 2 months prior to enrollment, or with central or cavitating lesions.\n* Radiologically documented evidence of major blood vessel invasion or encasement by cancer.\n* History of GI perforation and/or fistulae within 6 months prior to enrollment, or risk factors for perforation.\n* Uncontrolled intercurrent illness including, but not limited to, ongoing or active infection, symptomatic congestive heart failure, unstable angina pectoris, cardiac arrhythmia, or psychiatric illness/social situations that would limit compliance with study requirements.\n* Pregnancy\n* HIV-positive patients on combination antiretroviral therapy.",
    "miscellaneous_criteria": ""
}